BioNTech (NASDAQ:BNTX) CEO Sells $3,280,660.00 in Stock

Key Points

• BioNTech CEO Ugur Sahin sold 34,000 shares at an average price of $96.49, generating $3.28 million. The transaction, executed under a pre-arranged Rule 10b5-1 plan, reduced his ownership by 5.65% to 568,209 shares.
• Sahin has made several additional sales in September, selling more than 250,000 shares in total across the disclosed transactions.
• BioNTech shares recently traded at $95.83, while the company reported a quarterly loss and a 59.5% year-over-year revenue decline. Despite mixed analyst views, the stock carries a consensus “Moderate Buy” rating with a $126 price target.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 34,000 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00. Following the completion of the transaction, the chief executive officer owned 568,209 shares of the company's stock, valued at $54,826,486.41. This represents a 5.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded down $0.86 on Wednesday, hitting $95.83. 407,411 shares of the company were exchanged, compared to its average volume of 1,104,336. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock's 50 day moving average price is $97.13 and its 200 day moving average price is $95.10. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.23 billion, a P/E ratio of -12.24 and a beta of 1.29.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. BioNTech's revenue was down 59.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.60) earnings per share. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BNTX. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Berenberg Bank set a $140.00 price target on shares of BioNTech in a report on Wednesday. Morgan Stanley reduced their price target on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating for the company in a research report on Wednesday, July 8th. UBS Group restated a "buy" rating on shares of BioNTech in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioNTech in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

Institutional Trading of BioNTech

A number of hedge funds have recently modified their holdings of the stock. Flossbach Von Storch SE purchased a new stake in shares of BioNTech in the second quarter valued at approximately $207,142,000. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. First Trust Advisors LP grew its stake in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after acquiring an additional 451,124 shares during the period. Assenagon Asset Management S.A. acquired a new stake in BioNTech in the 2nd quarter valued at $39,385,000. Finally, SEB Asset Management AB purchased a new stake in BioNTech in the 1st quarter worth $17,804,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.